Skip to main content
Log in

Pharmacokinetics of Antimony in Patients Treated with Sodium Stibogluconate for Cutaneous Leishmaniasis

  • Published:
Pharmaceutical Research Aims and scope Submit manuscript

Abstract

The pharmacokinetics of Sb was examined in 29 patients with cutaneous leishmaniasis following the intramuscular administration of a dose of sodium stibogluconate equivalent to 600 mg of Sb. Blood was sampled at different time intervals from each patient and Sb was measured in whole blood by electrothermal atomic absorption spectrophotometry after an appropriate dilution with Triton X-100. The 24-hr urine- was also collected and analyzed similarly. The blood concentration-time data conformed to the one-compartment open model with mean and (SEM) of the apparent first-order rate constants for absorption (ka) and elimination (kd) of 1.71 (0.15) and 0.391 (0.016) hr−1, respectively. The maximum concentration of Sb achieved was 8.77 (0.39) mg/L and the peak time was 1.34 (0.09) hr. The total body clearance (TBC) and the volume of distribution (Vd) were 17.67 (1.38) L/hr and 45.7 (2.6) L, respectively, assuming a complete absorption. The fraction of dose of Sb excreted in the urine was 0.80 (0.07) and the renal clearance was 12.7 (1.16) L/hr. The frequency distribution pattern of the area-under-the-curve (AUC) appears to be bimodal and separates patients into those with low exposure to Sb (AUC = 11.7-29.04 mg.hr/L) (i.e., rapid eliminators) and those with high exposure to Sb (AUC = 31.5-49.1 mg.hr/ L) (i.e., slow eliminators). This may explain the variability observed in the response to treatment of leishmaniasis with sodium stibogluconate.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

REFERENCES

  1. D. J. B. Wijers. A ten year's study of kala-azar in Tharaka (Meru District, Kenya) II Relapses. East Afr. Med. J. 84:551–558 (1971).

    Google Scholar 

  2. L. Yan-Jia. A review of kala-azar in China from 1948 to 1959. Trans. Roy. Soc. Trop. Med. Hyg. 76:531–537 (1982).

    Google Scholar 

  3. A. D. M. Bryceson, J. D. Chulay, M. Ho, M. Mugambii, J. B. Were, R. Muigai, C. Chunge, G. Gachihi, J. Meme, G. Anabwani, and S. M. Bhatt. Visceral leishmaniasis unresponsive to antimonial drugs I. Clinical and immunological studies. Trans. Roy. Soc. Trop. Med. Hyg. 79:700–704 (1985).

    Google Scholar 

  4. S. Belazzoug and R. A. Neal. Failure of meglumine antimonate to cure cutaneous lesions due to Leishmania major in Algeria. Trans. Roy. Soc. Trop. Med. Hyg. 80:670–671 (1986).

    Google Scholar 

  5. S. Allen and R. A. Neal. The in vitro susceptibility of macrophages infected with amastigotes of Leishmania spp. to pentavalent antimonial drugs and other compounds with special relevance to cutaneous isolates. in D. T. Hart, (ed.), Leishmaniasis the Current Status and New Strategies for Control, Series A Life Sciences, 163:711–720 (1989).

  6. R. Kirk and M. H. Sati. Observation on the use of sodium antimony gluconate: (sodium stibogluconate in the treatment of kala-azar). Ann. Trop. Med. Hyg. 52:199–204 (1947).

    Google Scholar 

  7. E. Tuckman. Treatment of Chinese kala-azar with sodium antimony gluconate. J. Trop. Med. Hyg. 52:199–204 (1949).

    Google Scholar 

  8. T. McKenzie. Analytical data for the GTA-95. In E. Rothery (ed.), Analytical Methods for Graphite Tube Atomizer, Varian Techtron, Milgrave, Victoria, Australia, 1982, pp. 25–48.

    Google Scholar 

  9. M. Gibaldi and D. Perrier. Pharmacokinetics. Marcel Dekker, New York, 1975.

    Google Scholar 

  10. C. L. Pamplin, R. Desjardins, J. Chulay, E. Tramont, L. Hendricks, and C. Canfield. Pharmacokinetics of antimony during sodium stibogluconate therapy for cutaneous leishmaniasis. Clin. Pharmacol. Ther. 29:270–271 (1981).

    Google Scholar 

  11. J. D. Chulay, L. Fleckenstein, and D. H. Smith. Pharmacokinetics of antimony during treatment of visceral leishmaniasis with sodium stibogluconate or meglumine antimonate. Trans. Roy. Soc. Trop. Med. Hyg. 82:69–72 (1988).

    Google Scholar 

  12. P. H. Rees, P. A. Kager, M. I. Keating, and W. T. Hockmeyer. Renal clearance of pentavalent antimony (sodium stibogluconate). Lancet ii:226–229 (1980).

    Google Scholar 

  13. J. G. Dorea, E. Merchan-Hamann, D. E. Ryan, and J. Holzbecher. Retention of antimony in hair during leishmaniasis treatment. Clin. Chim. Acta 179:341–346 (1989).

    Google Scholar 

  14. J. D. Berman, J. D. Chulay, L. D. Hendricks, C. N. Oster. Susceptibility of clinical sensitive and resistant leishmania in vitro. Amer. J. Trop. Med. Hyg. 32:401–409 (1982).

    Google Scholar 

  15. J. D. Berman, J. F. Gallalee, and J. V. Gallalee. Pharmacokinetics of pentavalent antimony (Pentostam®) in hamsters. Amer. J. Trop. Med. Hyg. 39:41–45 (1988).

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

laser, M.A., El-Yazigi, A. & Croft, S.L. Pharmacokinetics of Antimony in Patients Treated with Sodium Stibogluconate for Cutaneous Leishmaniasis. Pharm Res 12, 113–116 (1995). https://doi.org/10.1023/A:1016251023427

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1016251023427

Navigation